Clinical Trial

Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting

Study acronym: PEGASO
Recruiting
View on ClinicalTrials.gov →
Summary
PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-07-09
notable Trial sites expanded: 1 -> 7 locations 2026-07-09
notable Primary completion pushed: 2028-12 -> 2029-02 2026-07-09
minor Completion pushed: 2028-12 -> 2029-02 2026-07-09
Trial Details
NCT Number NCT07109375
Lead Sponsor Chiesi Italia
Conditions Fabry Disease
Enrollment 75 participants
Start Date 2026-06-15
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-08